[Comment] Optimising late-line treatment administration in metastatic colorectal cancer: an even brighter SUNLIGHT

Offering late-line systemic therapy to patients with chemo-refractory metastatic colorectal cancer demands a careful estimation of the balance between the expected treatment benefit and its potential impact on quality of life, including adverse events, hospital visits, and psychosocial consequences.1 In such a comprehensive and individualised assessment of patients’ general conditions, usually summarised by Eastern Cooperative Oncology Group (ECOG) performance status, the cumulative burden of di